Prefrontal dysfunction in schizophrenia involves mixed-lineage leukemia 1-regulated histone methylation at GABAergic gene promoters by Huang, Hsien-Sung et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
Information Technology Publications and 
Presentations Information Technology Group 
2007-10-19 
Prefrontal dysfunction in schizophrenia involves mixed-lineage 
leukemia 1-regulated histone methylation at GABAergic gene 
promoters 
Hsien-Sung Huang 
University of Massachusetts Medical School 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/infoservices 
 Part of the Neuroscience and Neurobiology Commons, and the Psychiatry Commons 
Repository Citation 
Huang H, Matevossian A, Whittle C, Kim SY, Schumacher A, Baker SP, Akbarian S. (2007). Prefrontal 
dysfunction in schizophrenia involves mixed-lineage leukemia 1-regulated histone methylation at 
GABAergic gene promoters. Information Technology Publications and Presentations. https://doi.org/
10.1523/JNEUROSCI.3272-07.2007. Retrieved from https://escholarship.umassmed.edu/infoservices/34 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Information Technology 
Publications and Presentations by an authorized administrator of eScholarship@UMMS. For more information, please 
contact Lisa.Palmer@umassmed.edu. 
Neurobiology of Disease
Prefrontal Dysfunction in Schizophrenia Involves Mixed-
Lineage Leukemia 1-Regulated Histone Methylation at
GABAergic Gene Promoters
Hsien-Sung Huang,1,2 AnouchMatevossian,1 CatheryneWhittle,1 Se Young Kim,4 Armin Schumacher,4
Stephen P. Baker,3 and Schahram Akbarian1
1Brudnick Neuropsychiatric Research Institute, Department of Psychiatry, 2Graduate School of Biomedical Sciences, and 3Bioinformatics Unit, University
of Massachusetts Medical School, Worcester, Massachusetts 01604, and 4Department of Molecular and Human Genetics, Baylor College of Medicine,
Houston, Texas 77030
Alterations in GABAergic mRNA expression play a key role for prefrontal dysfunction in schizophrenia and other neurodevelopmental
disease.Here, we show that histoneH3-lysine 4methylation, a chromatinmark associatedwith the transcriptional process, progressively
increased at GAD1 and other GABAergic gene promoters (GAD2, NPY, SST) in human prefrontal cortex (PFC) from prenatal to peripu-
bertal ages and throughout adulthood. Alterations in schizophrenia included decreased GAD1 expression and H3K4-trimethylation,
predominantly in females and in conjunction with a risk haplotype at the 5 end of GAD1. Heterozygosity for a truncated, lacZ knock-in
allele of mixed-lineage leukemia 1 (Mll1), a histone methyltransferase expressed in GABAergic and other cortical neurons, resulted in
decreasedH3K4methylation at GABAergic gene promoters. In contrast,Gad1H3K4 (tri)methylation andMll1 occupancy was increased
in cerebral cortex of mice after treatment with the atypical antipsychotic, clozapine. These effects were not mimicked by haloperidol or
genetic ablation of dopamine D2 and D3 receptors, suggesting that blockade of D2-like signaling is not sufficient for clozapine-induced
histone methylation. Therefore, chromatin remodeling mechanisms at GABAergic gene promoters, including MLL1-mediated histone
methylation, operate throughout an extended period of normal human PFC development and play a role in the neurobiology of
schizophrenia.
Key words: nucleosome; epigenetic; single-nucleotide polymorphism; glutamic acid decarboxylase; interneuron; psychosis; cortical
development; aging
Introduction
Prolongedmaturation of prefrontal cortex (PFC), extending into
or even beyond the second decade, plays a key role for normal
human development and the neurobiology of major psychiatric
disease, including schizophrenia (Weinberger, 1987). In the ad-
olescent nonhuman primate PFC, dynamic changes in levels of
GABAergicmarker proteins suggest a role for inhibitory circuitry
(Lewis et al., 2004), but little is known about the underlying
molecular mechanisms. Traditionally, expression studies on
brain (including human) were confined to quantification of
mRNA and protein, but this approach does not discriminate be-
tween various cellular mechanisms such as gene transcription as
opposed to translational or other posttranscriptional regulatory
pathways. There is evidence, however, that psychosis and other
psychiatric disease are accompanied by molecular alterations re-
lated to epigenetic control of gene expression (Abdolmaleky et
al., 2004; Petronis, 2004; Grayson et al., 2005; Tsankova et al.,
2007). Here, we show that maturation of human PFC and rodent
cerebral cortex is accompanied by progressive increases in
GABAergic mRNA levels, including GAD1, which encodes a key
enzyme for GABA synthesis that is regulated by neuronal activity
(Benson et al., 1994) but frequently affected in schizophrenia and
related disease (Akbarian et al., 1995; Heckers et al., 2002; Veldic
et al., 2005; Lewis and Gonzalez-Burgos, 2006). These develop-
mentally regulated changes in mRNA levels were associated with
dynamic chromatin remodeling at GAD1/Gad1 and other
GABAergic gene loci, as reflected by increased methylation of
histone H3-lysine 4. This included the trimethylated form,
H3K4me3, a type of histone modification linked to transcrip-
tional mechanisms and RNA polymerase II activity (Hampsey
and Reinberg, 2003; Sims et al., 2003). We report that H3K4
methylation, including H3K4me3, was downregulated at Gad1
and other GABAergic genes in mice heterozygous for a targeted
allele of mixed-lineage leukemia 1 (Mll1), a histone methyltrans-
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ferase that was expressed at robust levels in cortical interneurons.
Interestingly, treatment with the atypical antipsychotic, cloza-
pine, resulted in increased Mll1 occupancy and H3K4me3 levels
at the Gad1/GAD1 promoter. Finally, we demonstrate that
schizophrenia subjects biallelic for GAD1 haplotypes previously
associated with schizophrenia and mood and anxiety disorders
(Addington et al., 2005; Lundorf et al., 2005; Hettema et al., 2006;
Straub et al., 2007) were affected by a deficit in prefrontal GAD1
mRNA, in conjunction with a shift from open (H3K4me3) to-
ward repressive (H3K27me3) chromatin-associated histone
methylation. These novel findings present the first evidence that
MLL1-mediated histone lysine methylation is an important reg-
ulator of GABAergic chromatin structures that are dynamically
regulated throughout an extended period of human PFC devel-
opment and involved in the pathophysiology of chronic psy-
chotic illness, including schizophrenia.
Materials andMethods
Human subjects. Human postmortem samples included in this study
were obtained from the dorsorostral pole of the frontal lobe, correspond-
ing to Brodmann’s area 10 of adult cortex. All procedures were approved
by the institutional review boards of the participating institutions. All
brains were fresh-frozen and stored at 80°C. The fetal, neonatal, and
child samples were obtained through the Brain and Tissue Banks for
Development Disorders, University of Maryland (National Institute of
Child Health and Human Development Contract NO1-HD-8-3284). In
addition, 50matched pairs of subjects diagnosed with schizophrenia and
matched controls were obtained from a brain bank located at the Uni-
versity of California (Davis, CA) and a brain bank at Maryland Psychiat-
ric Research Center (Baltimore, MD) (Akbarian et al., 2005). Matching
was done for gender and also for age and autolysis time (25%). All
matching procedures were completed before any experiment, including
genotyping and determination of RNA integrity numbers (RINs). When
an RIN value of 4.0 was chosen as the cutoff for acceptable RNA quality
(Lipska et al., 2006), 14 of 50 matched pairs were removed from this
study. Demographics, medication status, and postmortem confounds,
including tissue pH and RIN for the remaining 36 matched pairs are
provided in supplemental Table 1 (available at www.jneurosci.org as
supplemental material). Because none of these 36 cases had received
clozapine, an additional set of 9 cases (all treated with clozapine before
death) was obtained from theMaryland Psychiatric Research Center and
also the Bronx Veterans Affairs Medical Center, Mount Sinai School of
Medicine (Bronx, NY). The serum levels of clozapine in the toxicology
screens after death ranged from 0.7 to 5.6 mg/L. The 36 matched pairs of
this study include 10 matched pairs (4 females; 6 males) from a previous
study focused on GAD1 DNA cytosine methylation in PFC of schizo-
phrenia subjects (Huang and Akbarian, 2007).
Animal studies. For antipsychotic drug studies, adult male C57BL/6
mice, 10–15 weeks of age, were treated acutely or for 21 d with once daily
intraperitoneal injections of saline or haloperidol (0.5 mg/kg) or cloza-
pine (5 mg/kg) (Sigma, St. Louis, MO), and then killed 60 min after
the last treatment. Mutant mice included in this study (Mll1/,
Drd2/Drd3/) were 10–15 weeks of age and gender-matched to
animals froman outbred colony (Mll1) (Kim et al., 2007) or inbred strain
(Drd2/Drd3/, C57BL/6) (Glickstein et al., 2002). Cerebral cortex,
without hippocampus, was isolated, for RNA extraction (left hemi-
sphere) and chromatin immunoprecipitation (right hemisphere).
Cell cultures. Neural stem cells were prepared from forebrain of em-
bryonic day 14.5 (E14.5) SASCO SD rat embryos (Charles River, Wil-
mington, MA). Live cells were plated out at 1.2–1.4  106 cells per 100
mm poly-L-lysine-coated dishes precoated with 15 g/ml poly-L-
ornithine (Sigma) and 1 g/ml fibonectin (R&D Systems, Minneapolis,
MN), and treated daily with 10 g of basic fibroblast growth factor 2
(FGF2) (R&DSystems). At 5 d in vitro, cells were passaged and plated out
at 0.8–1.0 106 cells per precoated plate and expanded as above for an
additional 3–4 d (expansion, 300%). Cells were passaged again and
plated out at 1.2–1.4 106, and after 1–2 d FGF2was removed, cells were
washed once with media, and then resuspended in media without FGF2,
and harvested after 4 d.
Chromatin immunoprecipitation, mRNA studies, and histone prepara-
tion. Cortical gray matter (70–100 mg, human; 30–50 mg, mouse) was
stripped of adjacent white matter from the frozen blocks, and then ho-
mogenized and digestedwithmicrococcal nuclease for subsequent native
chromatin immunoprecipitation (NChIP) followed by quantitative PCR
(qPCR), exactly as described previously (Huang et al., 2006). For NChIP,
anti-H3-trimethyl-lysine 4 (anti-H3K4me3) and anti-H3-trimethyl-
lysine 27 (anti-H3K27me3) antibodies (Upstate, Lake Placid, NY) were
used, with rabbit serum as negative control. Specificity of each antibody
was monitored using dot blot assays with synthetic peptide (supplemen-
tal Fig. 2, available at www.jneurosci.org as supplemental material).
Primers pairs chosen for quantitative analyses had to pass two filters: (1)
reliable amplification of specific (sequence-verified) product and (2)
primer slope with 25% variation from the expected value, 1.4427.
Primer and genomic sequences are listed in supplemental Table 2 (avail-
able at www.jneurosci.org as supplemental material). To study Mll1 and
RNApol II occupancy, chromatin from extracted nuclei was prepared by
cross-linking in 1% buffered formaldehyde for 10 min, followed by son-
ication and immunoprecipitation with anti-Mll1 (Bethyl Laboratories,
Montgomery, TX) and anti-RNA pol II (Santa Cruz, Santa Cruz, CA)
antibodies.
Total RNA was isolated and purified from brains by using RNeasy
Lipid Tissue Mini kit (Qiagen, Valencia, CA). Samples were treated with
DNase I to avoid DNA contamination, then processed with TaqMan
One-Step RT-PCR (Applied Biosystems, Foster City, CA) with suitable
primers (supplemental Table 2, available at www.jneurosci.org as sup-
plemental material). From additional samples, biotinylated cRNA was
hybridized to custom-made Oligo GEArray Microarrays (Superarray
BioScience, Frederick,MD) according to themanufacturer’s instructions
and analyzed by using GEArray Expression Analysis Suite.
Bulk histone preparations from cerebral cortex,Western blot analysis,
and quantification of H3K4me2 and H3K4me3 levels were performed as
described previously (Kim et al., 2007).
In situ hybridization and cell counting. Brains were fixed in 4%
phosphate-buffered paraformaldehyde (4 h), and 14 m sections were
hybridized toDIG-11-UTP sense and antisense probes (15 ng per 25l of
hybridization buffer per section) at 60°C overnight, and thenwashed and
digestedwithRNaseA anddevelopedwith theDIGNuclei Acid detection
kit (Roche, Indianapolis, IN). The proportion ofGad1mRNA expressing
cells, relative to the -actin-expressing cells cut through the level of the
nucleus, was determined in 0.75 1.25 mm counting frames positioned
across the full thickness of the somatosensory cortex, using Bioquant
(Nashville, TN) software.
Immunocytochemistry. For immunocytochemistry, cultured cells were
fixed with phosphate-buffered 4% paraformaldehyde/0.2% glutaralde-
hyde, and then permeabilized with 0.2% Triton X-100 and blocked with
10% goat serum, and then incubated with primary antibody (anti-
Nestin,/-NeuN, -GABA) (Chemicon, Temecula, CA; and Sigma) for 1 h,
and then washed and incubated with Alexa 488- or 594-conjugated sec-
ondary antibodies (Invitrogen, Carlsbad, CA). For immunohistochem-
istry, brain sections were prepared as described above, and then pro-
cessed free-floating forMll1 and Gad1 immunoreactivity in conjunction
with Texas Red- and FITC-labeled secondary antibodies (Vector Labo-
ratories, Burlingame, CA), using standard protocols.
Genotyping. GAD1 single-nucleotide polymorphism (SNP) genotyp-
ingwas performed using direct sequencing, and alsomatrix-assisted laser
desorption/inonization mass spectrometry (Sequenom, San Diego, CA),
in conjunction with SpecroDesign software for PCR and MassEXTEND
primers (supplemental Table 2, available at www.jneurosci.org as sup-
plemental material).
Statistical analysis.Methylation and transcript profiles across genomic
loci, or age groups, or treatments in animals were evaluated by one-way
ANOVA followed by post hoc Tukey’s honestly significant difference
(HSD) or, in case of nonnormal distribution, by Kruskal–Wallis statistic
followed by Dunn’s test. Frequencies of cases that, in comparison with
matched control, showed mRNA deficits in conjunction with histone
methylation alterations were assessed with 2 3 contingency tables and
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Fisher–Freeman–Halton exact test. Case con-
trol (clinical samples) or mutant–wild-type
(mice) comparisons with nonnormal distribu-
tion was done by Wilcoxon’s signed-rank test;
otherwise, Student’s paired t test was applied.
Postmortem confounds, including tissue pH,
were assessed with Pearson’s correlation coeffi-
cient and did not show a significant effect on
any of the chromatin markers of this study.
Generalized effects of Mll1 gene dosage on
H3K4 methylation at GABAergic gene promot-
ers was assessed inMll1/ and/mice by
the binomial test. Levels of H3K4me2 and
H3K4me3 between wild-type and Mll1/
samples was analyzed statistically as described
previously (Kim et al., 2007).
Results
Dynamic changes inGAD1 expression
during human PFC development
To determine the regulation of GAD1 ex-
pression during maturation of human
PFC, we monitored GAD1 transcript from
the second trimester of pregnancy to old
age, using qRT-PCR (GAD1 and 18S rRNA
for normalization) in conjunction with
multiple primer pairs in 55 postmortem
samples. There was a progressive increase
in GAD1 mRNA levels throughout prena-
tal and postnatal development and child-
hood until the peripubertal stage, which
was followed by a plateau or mild decline
during subsequent aging (Fig. 1A). Devel-
opmental changes for GAD2, a glutamic
acid decarboxylase isoform encoded by a
different gene, were similar to GAD1 but
less pronounced. Levels were lowest in the
prenatal specimens, peaked before pu-
berty, followed by intermediate levels in
the adult [mean SEM, fetal, 4.5 0.9, vs
child (12 years of age), 11  1.4; p 
0.003, ANOVA Tukey’s HSD; adult, 7.0
1.0].
Progressive methylation of H3-lysine 4
at the GABAergic gene promoters
during PFC development
To find out whether a transcriptional
mechanism, including chromatin remod-
eling, contributes to this extended regula-
tion of GAD1mRNA expression, we mea-
sured histone lysine methylation levels at
theGAD1 locus in PFC nucleosomal prep-
arations, using NChIP (O’Neill and
Turner, 2003; Huang et al., 2006) in con-
junction with modification-specific anti-
histone antibodies, and rabbit serum as
negative control (Fig. 1B–E). In adult PFC,
open (H3K4) and repressive (H3K27)
chromatin-associated methylation marks
showed peak levels in nucleosomes posi-
tioned within the first 2 kb upstream
(H3K27) or downstream (H3K4) of the
GAD1 transcription start site (TSS) (Fig.
D
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Figure 1. Chromatin remodeling at GABAergic gene loci during development and maturation of human PFC. A, GAD1
mRNA levels in 55 subjects ranging in age from second trimester of pregnancy to old age (x-axis, log scale; B, birth or 0.77
years; P, puberty arbitrarily set at 12.77 years), expressed for each sample as mean SEM from three independent qPCR
amplicons/primer pairs after normalization to 18S rRNA ( y-axis). Notice progressive increase during prenatal and post-
natal development until puberty. B, Representative qPCR data from ChIP with anti-methyl-histone antibodies. Top,
Amplification curves of input (black), immunoprecipitates with anti-H3K27me3 (blue) and -H3K4me3 (red) antibodies
and no antibody as negative control (“no Ab”; green) as indicated. Bottom, SYBR Green-basedmelting curve and ethidium
bromide-stained 3% agarose gel, showing single peak inmelting curve corresponding to 122 bp product (GAD1, base pairs
440 to319). Arrowheads, 100 and 200 bp DNA ladder. C, Chip-to-input ratios for 10 primer pairs positioned across 20
kb of GAD1 sequence (x-axis) surrounding the TSS. CpG islands and exons I–III as indicated. N 8 –12 samples/primer
pair. Notice increased histone methylation in proximity of the TSS (Kruskal–Wallis, H3K4me3, p 0.001, and H3K27me3,
p 0.05). D, E, GAD1mRNA and histone lysine 4 methylation, H3K4me3 (D), and H3K4me1 (E), for GAD1, GAD2, SST, and
NPY promoters, the-globin locus control region and telomere-associated repeat 1 (TAR1). Data are expressed as mean
SEM for three age groups (fetal, 0 –12 years of age, and	12 years of age). Notice progressive and significant increase in
GAD1 mRNA (black) and GAD1-H3K4me3 and H3K4me1 levels (red) from prenatal to postnatal/child and from postnatal/
child to adolescent/adult stages, and similar profiles for GAD2, SST, and NPY. *p 0.01 compared with prenatal group,
Dunn’s test. F, Relative expression pattern (gray scale) of 30 histone methyltransferase enzymes and cofactors in fetal,
child, and adult PFC (N 5/group), as determined by oligonucleotide array.
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1C). Very similar findings were obtained for Gad1 chromatin
from mouse cerebral cortex (Fig. 2A). Therefore, regulation of
histone methylation in human and rodent cerebral cortex bears
similarities to various other tissues and cell lines for which clus-
tering of histone methylation signals around TSS in
chromosome-wide scans have been reported (Schneider et al.,
2004; Bernstein et al., 2005). Next, we monitored levels of
H3K4me3, and of H3-mono-methyl-lysine 4 (H3K4me1) [a re-
lated modification that partially overlaps with H3K4me3 in
genome-wide screens (Heintzman et al., 2007)] around GAD1
TSS during the course of PFC development. Similar to the pro-
gressive upregulation in GAD1mRNA levels, H3K4me3 levels at
the GAD1 promoter showed a severalfold increase from fetal to
childhood and from childhood to postpubertal/adult stages
(Kruskal–Wallis, p  0.001; Dunn’s test, p  0.01) (Fig. 1D).
Similar changes were observed for the monomethylated form,
H3K4me1 (Kruskal–Wallis, p 0.01; Dunn’s test, p 0.05) (Fig.
1E). This developmentally regulated increase in H3K4 trimethy-
lation and monomethylation at the GAD1 locus is not explained
by a generalized drift in histone methylation levels, because nu-
cleosomes positioned at the locus control region of the erythro-
poetic -globin locus, and around a telomere-associated DNA
repeat remained at very low levels throughout all stages of PFC
development (Fig. 1D). To examine whether GABAergic genes
other than GAD1 undergo chromatin re-
modeling during the course of PFC devel-
opment, we measured H3K4 methylation
at the 65 kDa glutamate decarboxylase
(GAD2), somatostatin (SST), and neu-
ropeptide Y (NPY) gene loci. All GABAer-
gic gene loci showed a developmental in-
crease in methylated H3K4 (Fig. 1D,E).
For the trimethylated form, H3K4me3,
levels were again highest in the postpuber-
tal/adult age group (GAD2, SST; Dunn’s
test, p  0.01) (Fig. 1D), whereas mono-
methylated H3K4 at these loci peaked dur-
ing childhood (GAD2, SST, NPY; Dunn’s
test, p 0.01) (Fig. 1E). We conclude that
developmentally regulated chromatin re-
modeling in human prefrontal cortex is
not limited to GAD1 but affects additional
GABAergic gene loci.
Chromatin remodeling at GABAergic
gene loci during
neuronal differentiation
Our studies on human postmortem PFC
suggest that histone methylation at
GABAergic gene promoters is dynamically
regulated during an extended period of de-
velopment. Next, we wanted to examine
whether similar mechanisms operate in
developing mouse cerebral cortex. Indeed,
H3K4me3 levels at the proximalGad1, Sst,
and Npy promoters, and the correspond-
ing gene transcripts, were progressively
upregulated during development ofmouse
cerebral cortex (Fig. 2B,D). Remarkably,
these dynamic changes continued beyond
postnatal day 18 (P18), or 10 d after the
density of cortical GABAergic neurons had
reached adult levels (one-way ANOVA
with Tukey’s HSD, p 0.05–0.001) (Fig. 2B).
These developmental changes in GABAergic mRNA expres-
sion and histone methylation shifts at the corresponding gene
promoters were further tested in neural precursor cells cultured
from E14.5 rat brain that differentiate into GABAergic and other
neurons on withdrawal of FGF2 from the medium (Fig. 3A,B)
(Laeng et al., 2004). As expected, Gad1 and Npy mRNA levels
were upregulated cultures treated by FGF2 withdrawal, whereas
changes in Sst transcript were not significant (Fig. 3C). Interest-
ingly, these effects on Gad1 and Npy expression were further
enhanced in cultures exposed to valproate or phenylbutyrate, two
short chain fatty acids acting as histone deacetylase inhibitors
(Fig. 3C). We conclude that expression of a subset of GABAergic
genes in neuronal culture is affected by exposure to chromatin
modifying drugs. Furthermore, the upregulation in Gad1/Npy
transcripts in these differentiated cultures was associated with
significant, 24-fold (Gad1) and fourfold (Npy) increases in the
open chromatin mark, H3K4me3, at the corresponding promoter
(Fig. 3D). In contrast, differentiation-related histone methylation
changes at the Sst gene locus weremore subtle and did not reach the
level of significance (Fig. 3D). Finally, the repressive chromatin
mark, H3K27me3, was downregulated at all three gene promoters
(Gad1/Npy/Sst) on differentiation (Fig. 3E).
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Figure 2. Histone H3methylation at GABAergic gene promoters in developingmouse cerebral cortex. A, Histonemethylation
profile of adult mouse cerebral cortex at Gad1 locus (x-axis) exons I–III and the three alternative promoters P1, P2, and P3 as
indicated. N 5 samples per primer pair. Notice the sharp rise in histone methylation in proximity of TSS (Kruskal–Wallis,
H3K4me3,p0.001;H3K27me3,p0.05).B, H3K4me3at 5endofGad1 (basepairs1048 to1145) (red) andGad1mRNA
(black) levels at different stages ofmouse cortical development (x-axis). Noticemarked increase for bothmarkers after P8 (*p
0.05–0.005, one-way ANOVA). C, Representative images through the full thickness of somatosensory cortex from P8 (left) and
P105 (right) sections hybridized with digoxigenin-labeled-actin or Gad1 antisense probes. The ratio of Gad1 to-actin
cells across the vertical thickness of cortex was similar for both age groups (mean SEM, P8, 0.107 0.003; P105, 0.127
0.033;N3/group). Scalebar, 50m.D, CoregulationofmRNA levels andhistoneH3K4-trimethylationduringmaturation from
P8 to P105 cortex for Npy (top) and Sst (bottom). *p 0.05, Student’s t test.
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The histone methyltransferase Mll1 is
expressed in cortical interneurons and
regulates H3K4methylation at
GABAergic gene promoters
To explore themolecularmechanisms that
regulate histone methylation at the GAD1
locus, custom-made oligonucleotide ar-
rays were used to profile the developmen-
tal expression pattern of 30 histone
methyltransferases and associated cofac-
tors, including four transcripts encoding
enzymes with H3K4 methyltransferase ac-
tivity (MLL1, MLL2, SMYD3, SET7) and
several cofactors specifically associated
with methylation of H3-lysine 4 (Fig. 1F).
Among the methyltransferase-encoding
transcripts, only MLL1 was expressed at
robust levels in the adult humanprefrontal
cortex (Fig. 1F) andmouse cerebral cortex
(Fig. 4B). Expression of Mll1 immunore-
activity was observed in numerous nuclei
positioned across the full vertical thickness
of the cerebral cortex (Fig. 4Aa). These in-
cluded a significant portion of GABAergic
interneurons as evidenced in sections dou-
ble labeled forMll1 andGad1 protein (Fig.
4Ab) or transcript (Fig. 4Ac).
These high levels of Mll1 immunoreac-
tivity in cortical interneurons would sug-
gest a role for that enzyme in the regula-
tion of GABAergic chromatin. Indeed,
there was robust Mll1 occupancy at the
proximalGad1 promoter inmouse P8 and
P105 cortical chromatin extracts prepared
by formaldehyde cross-linking and soni-
cation (Fig. 4C). It is thought that MLL1-
mediated H3K4 trimethylation is under the control of the tran-
scriptional process (Hampsey and Reinberg, 2003; Eissenberg
and Shilatifard, 2006). In dividing cells, the genome-wide posi-
tioning of Mll1 overlaps to 90% with RNA polymerase II occu-
pied regions (Guenther et al., 2005). Notably, mice homozygous
or heterozygous for a truncated Mll1 allele lacking the methyl-
transferase (SET) domain showed deficiencies inH3K4 trimethy-
lation and dimethylation (H3K4me3 and H3K4me2) at selected
Hox and other gene loci (Milne et al., 2005). Homozygosity for
this Mll1 allele is lethal at E10.5, and mutant embryos exhibit
segmentation defects in cranial ganglia and branchial arches (Yu
et al., 1995, 1998). Interestingly, recent analysis of newborn and
adult brain from viable Mll1/ mice identified increased Mll1
protein levels in conjunction with decreased in Mll1 mRNA ex-
pression, suggesting a posttranslational mechanism of Mll1 up-
regulation (Kim et al., 2007). Therefore, we examined H3K4me3
and H3K4me2 at Gad1/Sst/Npy in cerebral cortex of adult
Mll1/ animals. In the mutants, H3K4me3 was decreased by
42–57% and H3K4me2 by 15–31%, in comparison with controls
(Fig. 4D). These methylation changes at GABAergic promoters
were, as a group, significant [binomial test (6 of 6), p  0.03].
Notably, decreased promoter histone methylation in Mll1/
mice was not accompanied by consistent reductions in the corre-
sponding gene transcripts (data not shown), consistent with the
hypothesis that Mll1-mediated histone methylation operates
downstream from the transcriptional process (Hampsey and Re-
inberg, 2003; Eissenberg and Shilatifard, 2006). Furthermore,
bulk histone preparations revealed no statistically significant dif-
ference inH3K4me2 andH3K4me3 levels betweenwild-type and
Mll1 heterozygous brain (Fig. 4E). In the context of normal bulk
histone methylation, decreased H3K4 methylation at Gad1/Sst/
Npy suggests that Mll1 functions at a select number of target loci
in adult brain.
GAD1 SNPs are associated with chromatin alterations in
prefrontal cortex of schizophrenia subjects
We profiled GAD1 and GAD2 histone methylation patterns
(H3K4me3 and H3K27me3) and mRNA levels in a postmortem
collection of 36 schizophrenia subjects (12 females; 24 males),
using a case/control design. There were no significant alterations
in GAD2 mRNA and histone methylation levels (supplemental
Fig. 1A, available at www.jneurosci.org as supplemental mate-
rial). In contrast, significant deficits were observed for GAD1
mRNA and H3K4me3 levels in female, but not male schizophre-
nia subjects (Fig. 5A). Notably, schizophrenia in females is asso-
ciated with a later age of onset compared with males (Lieberman
et al., 2001). Therefore, it was remarkable that the deficits in
GAD1 mRNA and H3K4me3 in the schizophrenia cohort of the
present study showed a highly robust, inverse correlation with
age of onset (Fig. 5B). Themolecular mechanismsmediating this
gender- and age of onset-related effect remain to be explored. Inter-
estingly, prefrontalMLL1 expression was significantly higher in fe-
males compared with males; levels were similar in cases and con-
trols (supplemental Fig. 1B, available at www.jneurosci.org as
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supplemental material). Furthermore, the steep and progressive
increase in GAD1H3K4me3, which was observed during prepu-
bertal development (Fig. 1D), continued on amoderate level also
throughout subsequentmaturation and aging of normal prefron-
tal cortex (Fig. 5C). Therefore, histone methylation at the GAD1
locus, in addition to its regulation during early brain develop-
ment, is also a molecular mechanism potentially operating
throughout early and late stages of psychotic illness.
Several GAD1 SNPs confer genetic risk for increased rate of
frontal lobe gray matter loss, in conjunction with childhood on-
set and other types of schizophrenia (Addington et al., 2005;
Straub et al., 2007), and bipolar illness (Lundorf et al., 2005).
Given the proximity of these SNPs to the TSS ofGAD1 (Fig. 5D),
we hypothesized that changes in GAD1 chromatin structure
could contribute to cortical pathology in genetically susceptible
individuals. We genotyped GAD1 SNPs, and allele frequencies
were not significantly different between disease and control
brains (data not shown). A subset of three SNPs was selected for
additional analyses because	10% of cases were homozygous for
the rare allele, indicating sufficient statistical power. We then
determined the frequencies of cases that, in comparison with the
matched controls, showed decreased prefrontal GAD1 mRNA
levels, in conjunction with a decrease in the open chromatin
mark, H3K4me3 and elevated levels of the
repressive mark, H3K27me3. Given these
criteria, 35% of schizophrenia subjects
(male and female) (Fig. 5D) biallelic for the
GAD1 SNPs previously identified as risk
factors for schizophrenia (Addington et al.,
2005; Straub et al., 2007) or bipolar disor-
der (Lundorf et al., 2005) (Fig. 5D, geno-
type 1/1) were affected. Strikingly, none of
the other two genotypes (Fig. 5D, geno-
types 1/2 and 2/2) was affected. These dif-
ferences were significant (Fisher–Free-
man–Halton, p  0.05). For the matched
controls, there were no significant differ-
ences in distribution of allelic loads (data
not shown). We conclude that genetic
polymorphisms around the proximal
GAD1 promoter play an important role for
chromatin alterations and transcriptional
dysregulation in schizophrenia subjects.
Mll1 occupancy, and H3K4
trimethylation at theGad1 promoter in
cerebral cortex is selectively increased
after treatment with the atypical
antipsychotic clozapine
Previous studies reported increased Gad1
mRNA expression in rodent cerebral cor-
tex after antipsychotic drug treatment
(Lipska et al., 2003; Zink et al., 2004;
Chertkow et al., 2006). To test whether
chromatin remodeling is involved, Gad1
H3K4me3 levels were monitored after
daily injections of clozapine (5 mg/kg) for
21 d. Clozapine is an atypical antipsychotic
drug with relative efficiency in treatment-
resistant schizophrenia and for some of the
cognitive deficits of that disorder (Meltzer,
2004). Indeed, after chronic clozapine
treatment,Gad1-associated H3K4me3 was
increased threefold in cerebral cortex, in comparison with
vehicle-treated controls (one-way ANOVA, p 0.05) (Fig. 6A).
Because the pharmacological profile of clozapine extends beyond
antagonism of dopamine D2-like receptors, we also monitored
Gad1 H3K4me3 after chronic treatment with the conventional
antipsychotic and D2-like antagonist, haloperidol (0.5
mg  kg1  d1 for 21 d). No significant changes were observed
(Fig. 6A). Furthermore, no changes in H3K4 methylation were
observed in cortical Gad1 chromatin from compound mutant
mice homozygous for null alleles of Drd2 and Drd3 dopamine
receptor genes (Glickstein et al., 2002) (Fig. 6A). Therefore,
blockade of D2-like receptors is not sufficient for clozapine-
induced histone methylation at Gad1.
Notably,Mll1mRNAexpression inmouse cerebral cortexwas
increased after chronic clozapine treatment (Fig. 6B). In addi-
tion, Mll1 occupancy at theGad1 promoter showed a significant,
twofold increase after a single dose of 5 mg/kg clozapine (Fig.
6B). This clozapine-regulated Mll1 occupancy at Gad1 chroma-
tin was evident both at 30 min (236  72% relative to controls;
N 12) and 120 min after the injection (291 110% relative to
controls;N 12). In contrast,Gad1/Mll1 occupancy 30min after
a lower dose of clozapine (1mg/kg) remained unchanged relative
to controls (97  16%; N  6). Furthermore, the clozapine (5
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mg/kg)-mediated Mll1 recruitment at
Gad1 chromatinwas specific for that locus,
because Mll1 occupancy at the Sst pro-
moter was indistinguishable between
drug-treated animals and controls (data
not shown). We conclude that clozapine-
induced histone methylation at the Gad1
locus involves two mechanisms, including
increasedMll1 expression and recruitment
to the GABAergic promoter.
To investigate whether the effects of
clozapine on Gad1 methylation, as de-
scribed above for mouse cerebral cortex,
also apply to the human prefrontal cortex,
we obtained postmortem specimens from
another nine schizophrenia subjects that
were treated with clozapine before death.
In comparisonwith schizophrenia subjects
treatedwith typical antipsychotics but oth-
erwise closely matched for age, gender,
RNAquality, and allelic load forGAD1 risk
alleles (supplemental Table 1, available at
www.
jneurosci.org as supplemental material),
the clozapine-treated subjects showed on
average a twofold increase in H3K4me3 at
the GAD1 locus. This difference between
the two groups was significant (Fig. 6C). In
contrast, there were no consistent differ-
ences inH3K27me3 levels between the two
treatment groups. Furthermore, the
clozapine-treated subjects showed a mod-
est, albeit nonsignificant increase in
mRNA levels forGAD1 andMLL1 (supple-
mental Fig. 1C,D, available at www.
jneurosci.org as supplemental material).
Together, the animal studies and the hu-
man data support the notion that cloza-
pine positively regulates MLL1-mediated
histone methylation at the GAD1 locus.
Discussion
We report that maturation of human and
rodent cerebral cortex is reflected by a pro-
gressive increase in histone H3-lysine 4
methylation at GABAergic gene promot-
ers. Regulation of chromatin structures at a
subset of GABAergic gene loci, including
GAD1/Gad1, was dependent on normal
gene dosage for Mll1, a histone methyl-
transferase expressed in GABAergic inter-
neurons. These chromatin remodeling
mechanisms are likely to play an important
role for schizophrenia-related pathophysiology, because Gad1/
GAD1-associated H3K4 methylation, and Mll1 occupancy, were
upregulated after treatment with the atypical antipsychotic clo-
zapine, a drug that improves working memory and other frontal
lobe-associated cognitive functions (Meltzer, 2004). Notably,
polymorphisms around the GAD1 promoter previously associ-
ated with schizophrenia and accelerated loss of frontal lobe gray
matter (Addington et al., 2005; Straub et al., 2007) also confer,
according to the present study, deficits in gene expression and
histone methylation alterations in schizophrenia brain. There-
fore, Mll1/MLL1-mediated histone lysine methylation at
GABAergic gene loci emerges as a molecular link that intercon-
nects three major factors in the neurobiology of psychosis: devel-
opmental mechanisms, interneuron dysfunction, and antipsy-
chotic pharmacotherapy.
Importantly, the present study faces two limitations. First, it
remains unclear why the observed deficits in GAD1mRNA levels
and H3K4 methylation occur predominantly in female subjects
with schizophrenia (Fig. 5A). Notably, the genetic association of
GAD1 haplotypes with schizophrenia is reportedly more robust
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in females than in males (Addington et al., 2005; Straub et al.,
2007). It remains possible that the gender-specific effects in these
genetic studies and in the present postmortem study are, at least
in part, attributable to higher levels ofMLL1 expression in PFC of
females compared with males (supplemental Fig. 1B, available at
www.jneurosci.org as supplementalmaterial). Second, it remains
unclear whether and how the observed upregulation of H3K4
methylation at the Gad1/GAD1 promoter of clozapine-treated
mice (Fig. 6A) and human subjects (Fig. 6B) reflects functional
changes in the cortical GABAergic system, given that the corre-
sponding changes in steady-state GAD1mRNA levels were more
subtle and without statistical significance (supplemental Fig. 1D,
available at www.jneurosci.org as supplemental material). Nota-
bly, evidence from animal models suggest that clozapine, in con-
trast to conventional antipsychotic drugs blocking D2 receptors,
selectively improves GABAergic circuitry functions in cerebral
cortex (Pillai-Nair et al., 2005) possibly by enhancing inhibitory
inputs onto pyramidal neurons through a network-based mech-
anism (Gao, 2007). In agreement with this hypothesis, clozapine-
regulatedmethylation of GABAergic chromatin, as reported here
for the animal and human brain, requires functional brain cir-
cuitry, because Gad1-H3K4 methylation remains unaffected in
neuronal cultures treated with clozapine (Huang and Akbarian,
2007). Therefore, additional studies will be necessary to explore
the link between GABAergic chromatin remodeling and the elec-
trophysiological changes (Gao, 2007) after clozapine treatment.
Beyond its biochemical function as a histone methyltrans-
ferase with specificity for H3 lysine 4 (Milne et al., 2002), recent
evidence points to a distinct developmental role of Mll1 in the
CNS. This was evident from segmentation defects in cranial gan-
glia in Mll1/ embryos (Yu et al., 1998), as well as abnormal
synaptic plasticity in the hippocampus of Mll1/ adult mice
(Kim et al., 2007). In support of multiplicity of function, Mll1
undergoes highly regulated proteolytic cleavage (Yokoyama et
al., 2002) and was recently detected in a complex with the Poly-
comb protein Eed and repressive chromatin remodeling in the
adult brain (Kim et al., 2007). This suggests that Mll1 regulates
CNS circuitry through several mechanisms operating at different
stages of development, as well as in adult brain. Furthermore, the
dynamics and molecular machineries regulating histone methyl-
ation and demethylation (Tahiliani et al., 2007) in CNS await
additional investigations.
It will also be of interest to find out whether or not GAD1
H3K4 histone hypomethylation in schizophrenia, as reported
here, is accompanied by epigenetic modifications of the genomic
DNA, including methylation of CpG dinucleotides. However,
according to a preliminary study on a small subset of CpGs posi-
tioned in the 5 portion of GAD1, DNA cytosine methylation
frequencies at theGAD1 promoter are very low in normal human
PFC (5%) and potentially even further decreased in repressive
(H3K27me3) but not open (H3K4me3) chromatin of schizo-
phrenia subjects (Huang and Akbarian, 2007). Therefore, com-
prehensivemapping ofmultiple histonemodifications, andDNA
CpG methylation tags, at GAD1 and other GABAergic gene loci
will be necessary to better understand epigenetic regulation of
GABAergic gene expression in healthy and diseased human PFC.
It is remarkable that, according to the present study, chroma-
tin structures in prefrontal cortex are subjected to progressive
changes from prenatal to peripubertal stages. In addition, this
process continues at some gene loci, including GAD1, through-
out adulthood into old age. This implies that chromatin remod-
eling and transcriptional mechanisms function as part of a mo-
lecular “clock” that regulates, over the course of many years, the
protracted maturation, and perhaps also subsequent aging, of
prefrontal GABAergic circuitry. To gain additional insight into
this clock bears great promise for a better understanding of nor-
mal human development, including possible alterations in
schizophrenia and related disease.
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